Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Cash & Equivalents (2016 - 2025)

Ascendis Pharma A (ASND) has disclosed Cash & Equivalents for 10 consecutive years, with $717.1 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 19.93% to $717.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $717.1 million through Dec 2025, up 19.93% year-over-year, with the annual reading at $717.1 million for FY2025, 19.93% up from the prior year.
  • Cash & Equivalents hit $717.1 million in Q4 2025 for Ascendis Pharma A, up from $597.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $717.1 million in Q4 2025 to a low of $421.9 million in Q4 2023.
  • Historically, Cash & Equivalents has averaged $540.3 million across 5 years, with a median of $510.5 million in 2021.
  • Biggest five-year swings in Cash & Equivalents: dropped 26.75% in 2021 and later skyrocketed 41.71% in 2024.
  • Year by year, Cash & Equivalents stood at $510.5 million in 2021, then fell by 11.12% to $453.8 million in 2022, then fell by 7.01% to $421.9 million in 2023, then soared by 41.71% to $597.9 million in 2024, then increased by 19.93% to $717.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for ASND at $717.1 million in Q4 2025, $597.9 million in Q4 2024, and $421.9 million in Q4 2023.